Of note, ALT-positive cancers are not all alike, and apart from differences in telomere maintenance may differ in replication timing and efficiency of cell cycle checkpoint activation, characteristics that in turn may impact lesion propagation through mitosis and the use of post-MiDAS. The gene discussed is GPT; the disease is cancer.